Program for stress reduction and lifestyle changes in IBS patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of a 10-week multimodal stress reduction and lifestyle modification program for patients with irritable bowel syndrome (IBS). The program includes group sessions focused on stress management, physical activity, dietary changes, and self-help strategies. Participants will be divided into an intervention group receiving the program and a waitlist control group that will receive educational materials. The study aims to assess the program's impact on IBS symptom severity, quality of life, and mental well-being using validated measurement scales.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* confirmed diagnosis of irritable bowel syndrome (IBS with diarrhea, IBS with constipation, mixed-type IBS, or unspecified IBS); IBS-SSS Score \> 75

Exclusion Criteria:

* Severe mental illness (e.g., clinically significant depression, substance use disorder, schizophrenia)
* Severe comorbid somatic illness (e.g., oncological disease)
* Pregnancy
* Participation in other stress reduction programs or clinical studies on psychological interventions
* Known intolerances (fructose, lactose), celiac disease, etc.

Where it's running

• Sozialstiftung Bamberg
  Bamberg, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Jost Langhorst, Prof. Dr. — University of Duisburg-Essen/Sozialstiftung Bamberg
• Study coordinator: Sandra Utz, PhD
• Email: sandra.utz@sozialstiftung-bamberg.de
• Phone: +49 951 503

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity

  This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.

  Recruiting at 2 sites University of Palermo · Palermo, Palermo and 1 other locations · NCT07750535

• Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome

  This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07581756

• Brenipatide (LY3537031) for IBS with constipation

  This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.

  Recruiting at 64 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 69 other locations · NCT07545772

• Brenipatide (LY3537031) treatment for adults with IBS‑D

  This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.

  Recruiting at 80 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 88 other locations · NCT07545759

• Camlipixant for IBS-D and IBS-M: a test in adults

  This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.

  Recruiting at 114 sites Phase 2 GlaxoSmithKline · Anniston, Alabama and 113 other locations · NCT07519395

• Defining Objective Markers of Dietary Compliance in IBS

  This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT07494968

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.